2 weeks Ago By ABMN Staff
Shares of uniQure ( NASDAQ:QURE – Get Free Report ) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $5.63 and traded as low as $4.
98. uniQure shares last traded at $5.08, with a volume of 511,269 shares.
Analyst Ratings Changes A number of research firms have issued reports on QURE. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 target price on shares of uniQure in a research report on Friday, September 20th.
The Goldman Sachs Group raised their price objective on shares of uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd.
HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a research report on Tuesday, August 20th. Finally, StockNews.
com upgraded uniQure to a “sell” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, uniQure has an average rating of “Hold” and a consensus price target of $19.
40. Read Our Latest Stock Report on uniQure uniQure Price Performance uniQure ( NASDAQ:QURE – Get Free Report ) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.
16) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.08.
uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%.
The business had revenue of $11.13 million during the quarter, compared to the consensus estimate of $3.47 million.
On average, sell-side analysts predict that uniQure will post -4.04 EPS for the current year. Institutional Investors Weigh In On uniQure Several hedge funds have recently added to or reduced their stakes in QURE.
China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 58.
5% in the 1st quarter. China Universal Asset Management Co. Ltd.
now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 3,664 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in shares of uniQure by 21.0% during the second quarter.
Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares during the last quarter. Total Clarity Wealth Management Inc. bought a new stake in shares of uniQure during the second quarter worth about $74,000.
SG Americas Securities LLC acquired a new stake in shares of uniQure in the 2nd quarter worth about $79,000. Finally, Cubist Systematic Strategies LLC lifted its position in uniQure by 130.9% in the 2nd quarter.
Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 14,454 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.
About uniQure ( Get Free Report ) uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. See Also Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.
com's FREE daily email newsletter ..
